• 1
    Hewitson P,Glasziou P,Watson E,Towler B,Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am. J Gastroenterol 2008; 103: 15419.
  • 2
    Allison JE,Tekawa IS,Ransom IJ,Adrain AL. A comparison of fecal occult blood tests for colorectal cancer screening. N Engl J Med 1996; 334: 1559.
  • 3
    Launoy GD,Bertrand HJ,Berchi C,Talbourdet VY,Guizard AV,Bouvier VM,Caces ER. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer 2005; 115: 4936.
  • 4
    Morikawa T,Kato J,Yamaji Y,Wada R,Mitsushima T,Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129: 4228.
  • 5
    Guittet L,Bouvier V,Mariotte N,Vallee JP,Arsène D,Boutreux S,Tichet J,Launoy G. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average-risk population. Gut 2007; 56: 2104.
  • 6
    Castiglione G,Visioli CB,Ciatto S,Grazzini G,Bonanomi AG,Rubeca T,Mantellini P,Zappa M. Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme. Br J Cancer 2007; 96: 17504.
  • 7
    Allison JE,Sakoda LC,Levin TR,Tucker JP,Tekawa IS,Cuff T,Pauly MP,Shlager L,Palitz AM,Zhao WK,Schwartz JS,Ransohoff DF, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99: 146270.
  • 8
    Van Rossum LG,van Rijn AF,Laheij RJ,van Oijen MG,Fockens P,van Krieken HH,Verbeek AL,Jansen JB,Dekker E. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 8290.
  • 9
    Fletcher RH. Commentary. ACP J Club 1996; 124: 74.
  • 10
    Allison JE. Colon cancer screening guidelines 2005: the fecal occult blood test option has become a better FIT. Gastroenterology 2005; 129: 7458.
  • 11
    Imperiale TF. Quantitative immunochemical fecal occult blood tests: is it time to go back to the future? Ann Intern Med 2007; 146: 30911.
  • 12
    Mandel JS. Which colorectal cancer screening test is best? J Natl Cancer Inst 2007; 99: 14245.
  • 13
    Ransohoff DF. What is the role of iFOBT in screening for colorectal cancer? Gut 2007; 56: 13434.
  • 14
    Castiglione G,Grazzini G,Miccinesi G,Rubeca T,Sani C,Turco P,Zappa M. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen 2002; 9: 99103.
  • 15
    Edwards JB. Screening for colorectal cancer using faecal blood testing: varying the positive cut-off value. Pathology 2005; 37: 5658.
  • 16
    Levi Z,Rozen P,Hazazi R,Vilkin A,Waked A,Niv Y. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Int Med 2007; 146: 24455.
  • 17
    Ciatto S,Martinelli F,Castiglione G,Mantellini P,Rubeca T,Grazzini G,Bonanomi AG,Confortini M,Zappa M. Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer 2007; 96: 21821.
  • 18
    Schatzkin A,Connor RJ,Taylor PR,Bunnag B. Comparing new and old screening tests when a reference procedure cannot be performed on all screenees. Example of automated cytometry for early detection of cervical cancer. Am J Epidemiol 1987; 125: 6728.
  • 19
    Cheng H,Macaluso M. Comparison of the accuracy of two tests with a confirmatory procedure limited to positive results. Epidemiology 1997; 8: 1046.
  • 20
    Chock C,Irwig L,Berry G,Glasziou P. Comparing dichotomous screening tests when individuals negative on both tests are not verified. J Clin Epidemiol 1997; 50: 12117.
  • 21
    Guittet L,Launoy G. Diagnostic accuracy of immunochemical faecal occult blood tests according to number of samples and positivity threshold. J Med Screen 2008; 15: 489.
  • 22
    Cole SR,Young GP,Esterman A,Cadd B,Morcom J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 2003; 10: 11722.
  • 23
    Berchi C,Bouvier V,Réaud JM,Launoy G. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ 2004; 13: 22738.
  • 24
    DeLong ER,DeLong DM,Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 83745.
  • 25
    Zhang DD,Zhou XH,Freeman DH,Freeman JL. A non-parametric method for the comparison of partial areas under ROC curves and itsapplication to large health care data sets. Stat Med 2002; 21: 70115.